Here’s whether Royalty Pharma plc Class A Ordinary Shares (RPRX) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.41% over 10 days); RSI 52 — healthy momentum range; strong 1-year return of +55.6%; 3-month momentum positive (+19.0%). Currently 2.9% off its 52-week high. Score: +7/7.
RPRX is in a confirmed uptrend, trading above both its 50-day ($51.52) and 200-day ($42.99) moving averages. An RSI of 51.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +55.6% compares to +22.9% for SPY (beat the market by 32.7%).
$10,000 invested 1 year ago→ $15,557 today
vs. S&P 500 (SPY) — same period beat market by 32.7%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($42.99)
✓Above 50-day MA ($51.52)
✓RSI(14) neutral zone (30–70) — currently 51.8
✓Positive return (+55.6%)
✓Within 10% of period high (−2.9%)
Period Range $54.87
$34.08$56.50
RSI (14) 51.8
0 · OversoldOverbought · 100
Key Metrics
Price$54.87
Period Return+55.6%
Period High$56.50
Period Low$34.08
Drawdown−2.9%
MA-50$51.52
MA-200$42.99
RSI (14)51.8
Avg Volume (30d)4.2M
vs. SPYbeat by 32.7%
Return Rank#325 of 1246
Trend Signals
Price is above the 200-day moving average ($42.99)